FSD Pharma Breaks All-time Daily Volume Record and Continues to Make History
- Today there is no cure for Multiple Sclerosis (MS). FSD Pharma will attempt to change that for millions of suffering people. FSD’s proprietary compound Lucid-MS has shown promising results to reverse progressive MS, in several animal models.
- Strategically advancing drug candidate pipelines focused on novel and unique therapies for neurodegenerative and psychiatric disorders.
- Well-capitalized to pursue acquisitions that present compelling opportunities across the psychedelics and innovative biotech space focused on Total Brain Health.
- Unique CAP structure with over 150,000 shareholders as of July 29, 2021.
- Balance sheet is free of debt and has over US $43.2M in cash as of June 30, 2021.
RECENT POSTS
Don't wait any longer, this is your opportunity to invest
Get more information on why to invest in FSD Pharma (CSE: HUGE NASDAQ: HUGE FRA: 0K9A) how to do it and why we recommend it. Sign up and get our investor deck PDF Document.